A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms RISE-SSc
  • Sponsors Bayer
  • Most Recent Events

    • 17 Jun 2017 Baseline characteristics presented at the 18th Annual Congress of the European League Against Rheumatism
    • 13 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Dec 2017.
    • 13 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top